Gender differences in corydaline pharmacokinetics in rats.

Area of Science:

• Pharmacology
• Pharmacokinetics
• Natural Products

Background:

• Corydaline is a key active component in the prokinetic botanical agent DA-9701.
• Preclinical pharmacokinetic studies of natural medicines should ideally include both male and female subjects.
• Understanding gender-based pharmacokinetic differences is crucial for accurate drug development.

Purpose of the Study:

• To evaluate the pharmacokinetic differences of corydaline between male and female rats.
• To assess the impact of gender on corydaline's absorption, distribution, metabolism, and excretion (ADME) following intravenous and oral administration of pure corydaline or DA-9701.

Main Methods:

• Intravenous and oral administration of corydaline and DA-9701 to male and female rats.
• Plasma concentration-time profiles were analyzed to determine pharmacokinetic parameters like AUC and Cmax.
• In vitro metabolism studies using male and female rat hepatic microsomes and human liver microsomes.

Main Results:

• Female rats showed significantly higher area under the plasma concentration-time curve (AUC) for corydaline after intravenous administration compared to males, attributed to reduced non-renal clearance.
• Oral administration of corydaline or DA-9701 resulted in substantially greater AUC and Cmax values in female rats versus males, indicating higher bioavailability.
• Slower corydaline metabolism in female rat hepatic microsomes, mediated by male-specific or dominant CYP isozymes, explains the observed gender differences in rats.

Conclusions:

• Significant gender-based pharmacokinetic differences exist for corydaline in rats, with females exhibiting greater exposure.
• These differences in rats are linked to gender-specific hepatic metabolic pathways involving cytochrome P450 enzymes.
• Comparable corydaline metabolism in human liver microsomes suggests that these gender differences observed in rats are unlikely to translate to humans.